From pomegranate to cellular cleaner: What is Urolithin A?
It begins with a pomegranate, more precisely with the polyphenols in its peel, known as ellagitannins. When we drink pomegranate juice or eat walnuts, raspberries, or strawberries, these plant compounds reach the large intestine. There, a highly specialized community of gut bacteria can convert ellagitannins into a substance that has become the subject of intensive aging research in recent years: Urolithin A.
What makes this compound so remarkable is not its origin, but its effects. Urolithin A activates a cellular cleaning process called mitophagy, the targeted breakdown and replacement of damaged mitochondria. Mitochondria are the power plants of our cells. As we age, damage to their DNA accumulates. Damaged mitochondria function inefficiently, produce less energy, and release more harmful oxygen radicals. [1]
Research on Urolithin A has gained significant momentum since 2016. In 2024 alone, more than 125 scientific papers on this substance were published. Four placebo-controlled human studies are now available, which is unusually many for a longevity compound.
The microbiome determines who benefits
The first hurdle is in the gut. Not everyone can produce Urolithin A naturally. A study of 100 healthy adults showed that only about 40% of participants developed significant levels of Urolithin A in their blood after drinking pomegranate juice. [2]
The cause lies in the individual composition of the gut microbiome. Researchers distinguish three so-called urolithin metabotypes: UM-A (efficient producers), UM-B (low production), and UM-0 (no production). The type a person belongs to depends on certain bacterial strains and can only be influenced to a limited extent through diet. [3]
Direct supplementation bypasses this problem. In studies, a single 500 mg dose led to plasma levels six times higher than those achieved after drinking pomegranate juice, regardless of metabolotype. [2]
How Urolithin A renews mitochondria
Urolithin A activates the PINK1/Parkin pathway, a central signaling pathway for mitophagy. In this process, damaged mitochondria are identified by the cell's machinery, packaged into autophagosomes, and broken down. New, functional mitochondria are formed from the breakdown products. This process declines with age, affecting muscle strength, immune function, and cognitive performance.
This mechanism is closely related to general autophagy, which spermidine also activates. Urolithin A specifically targets mitochondria, while spermidine initiates the broader cellular recycling process. Basic research began in 2016 with a Nature Medicine publication by ETH Lausanne. [4]
What clinical studies show and what they do not
There are now four placebo-controlled human studies. That provides a solid foundation for a longevity compound, but with important limitations that must be considered honestly when interpreting the evidence.
The first study was Andreux et al. in 2019 in Nature Metabolism: 60 healthy, sedentary older adults received urolithin A for four weeks. The result was proof of concept: safe, well tolerated, and associated with measurable improvements in mitochondrial biomarkers. It was the first evidence that the mechanism also activates in the human body. [5]
The most extensive efficacy study to date was published by Singh et al. in 2022 in Cell Reports Medicine. Eighty-eight overweight, sedentary adults between 45 and 65 received 500 or 1,000 mg of urolithin A daily for four months. The results showed a significant improvement of around 12% in leg muscle strength and a reduction in the inflammatory marker CRP. Importantly, the primary endpoint, peak power output, did not improve significantly. The positive strength and endurance findings were secondary endpoints. [6]
A second study from the same year, Liu et al. in JAMA Network Open, examined an older population: 66 adults between 65 and 90 received 1,000 mg daily for four months. Significant improvements in muscular endurance were already evident after two months, and acylcarnitines and CRP decreased measurably. Here too, the study failed to meet its primary endpoint: the 6-minute walk test and ATP production in the hand muscle did not improve significantly compared with placebo. [7]
Both studies show a consistent pattern: muscular endurance and inflammatory markers improve reliably, while the primary performance endpoints improve only partially. This is an honest picture, not a failure, but neither is it an unqualified success.
The MitoImmune study by Denk et al., published in Nature Aging in 2025, expanded the focus to the immune system. Fifty healthy adults aged 45 to 70 received 1,000 mg of Urolithin A daily for 28 days. The fatty acid oxidation capacity of CD8+ T cells increased significantly (+14.7 percentage points, p=0.006), and mitochondrial biogenesis in immune cells increased. [8] These findings suggest that Urolithin A may support not only muscle cells but also immune cells in maintaining mitochondrial function with age.
In addition, a smaller study by Zhao et al. 2024 in the Journal of the International Society of Sports Nutrition followed 20 trained male athletes for eight weeks. Muscle strength, endurance, and exercise-induced inflammatory markers improved significantly. [9] The sample is very small and exclusively male, limiting generalizability, but the finding shows that Urolithin A may also work in people who are already trained.
Promising for brain health: no human data yet
Urolithin A can cross the blood-brain barrier. [10] In three mouse models of Alzheimer's disease, long-term treatment improved learning and memory performance, and reduced amyloid-beta and tau pathologies. [11] Human clinical studies are still pending. An ongoing study with around 650 participants is the first to systematically investigate its effects on brain health in humans. Until its results are available, the animal and mechanistic data are biologically plausible, but do not constitute evidence of an effect in humans.
Safety profile and dosage
A 2024 systematic review involving more than 250 participants confirmed the favorable safety profile. [12] Urolithin A is not genotoxic. [13] GRAS status in the US, Novel Food authorization in the EU. Long-term data beyond four months are lacking. This does not mean that the compound is unsafe, but that research is still in its early stages.
Dosage according to current evidence: 500-1,000 mg daily, taken in the morning with a meal.
State of the evidence
The evidence base is comparatively robust for a longevity compound. Four human RCTs are available, two of which failed to meet their primary endpoint. Sample sizes remain small (20-88 participants), and long-term data are lacking.
| Level of evidence | Study type | Finding | Assessment |
|---|---|---|---|
| Human studies | RCT (n=88, age 45-65) | Muscle strength +12%, endurance ↑, CRP ↓ after 4 months. Primary endpoint (Peak Power Output) not significant. (Singh et al. 2022, Cell Rep Med) | 🟢 Strong, largest human efficacy study |
| Human studies | RCT (n=66, age 65-90) | Significant improvement in muscle endurance (hand + leg) after 2 months. Primary endpoint (6MWT, ATP) not significant. (Liu et al. 2022, JAMA Netw Open) | 🟢 Strong, primary endpoint not met |
| Human studies | RCT (n=50, 45–70 years) | CD8+ T-cell function ↑, FAO capacity +14.7 pp., mitochondrial biogenesis ↑ (Denk et al. 2025, Nat Aging) | 🟢 Strong, immunological effects demonstrated |
| Human studies | RCT (n=66, 65+) | First human safety and efficacy study, mitochondrial biomarkers ↑ (Andreux et al. 2019, Nat Metab) | 🟢 Strong, proof of concept |
| Human studies | RCT (n=20, athletes) | Muscle strength and endurance ↑ in trained men after 8 weeks (Zhao et al. 2024, JISSN) | 🟡 Moderate, small sample, men only |
| Animal model | Mouse study | Mitophagy activation, extended lifespan in C. elegans; improved muscle function in aging mice (Ryu et al. 2016, Nat Med) | 🟡 Limited, transferability to humans remains unclear |
| Mechanistic | In vitro / cell culture | Mitophagy activation via the PINK1/Parkin pathway in mammalian cells; passage across the blood-brain barrier demonstrated | 🔵 Foundation, mechanism explained |
| Gaps | Missing data | No long-term studies >4 months. No human studies on brain health. No direct evidence for longevity. Two RCTs failed to meet their primary endpoint. | 🔴 Open questions, critical considerations |
🟢 Strong evidence (human RCT) · 🟡 Moderate evidence · 🔵 Mechanistic evidence · 🔴 Missing data / limitations
Who can benefit from Urolithin A?
Based on the evidence to date, the substance is particularly relevant for people aged 40 and over, whose mitochondrial function declines with age. In addition, around 60% of the population cannot efficiently produce urolithin A from food. This group benefits especially from direct supplementation. Active people and athletes who want to specifically support muscle recovery and endurance capacity can also find concrete indications in the available data.
Urolithin A differs mechanistically from NMN (NAD+ increase) and spermidine (general autophagy). The three approaches target different levels of cellular health and can be combined.
What does this mean in practice?
Urolithin A is not a miracle pill. It is a substance whose mechanism of action is well understood and for which clinical data in humans are available. That is by no means a given for a longevity compound. The findings on muscle endurance and inflammatory markers are consistent. Two studies failed to meet their primary endpoint, which should be taken into account when forming a personal assessment.
